Sclerosis News and Research

RSS

Oral laquinimod shows promise against multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced the presentation of Phase III clinical and pre-clinical data, which collectively demonstrate that once-daily oral laquinimod modulates the pathological processes of multiple sclerosis to impact disease activity, disability progression and brain volume loss.

19 Oct 2011

Melbourne Brain Centre to open on Monday

Melbourne will become a magnet for the world's best and brightest brain researchers after the official opening of the Melbourne Brain Centre at The University of Melbourne Parkville by the Premier Ted Baillieu and Federal MP Michael Danby on Monday.

19 Oct 2011

Circadian disruption and sleep restriction increase risk of MS in teens

Researchers from Sweden have uncovered an association between shift work and increased risk of multiple sclerosis. Those who engage in off-hour employment before the age of 20 may be at risk for MS due to a disruption in their circadian rhythm and sleep pattern. Findings of this novel study appear today in Annals of Neurology, a journal published by Wiley-Blackwell on behalf of the American Neurological Association and Child Neurology Society.

18 Oct 2011

Brain tumour discovery offers drug treatment hope

Australian scientists have played a key role in the identification of a new biochemical mechanism that allows brain tumours to survive and grow, offering hope of new drug treatments for some of the most aggressive tumours.

17 Oct 2011

Brain stem cell treatment for multiple sclerosis

The prospect of doing human clinical trials with stem cells to treat diseases like multiple sclerosis may be growing closer, say scientists at the University at Buffalo and the University at Rochester, who have developed a more precise way to isolate stem cells that will make myelin.

15 Oct 2011

Scientists characterize and isolate potential stem cells to treat MS, myelin disorders

Scientists have improved upon their own previous world-best efforts to pluck out just the right stem cells to address the brain problem at the core of multiple sclerosis and a large number of rare, fatal children's diseases.

14 Oct 2011

U of U researchers receive NIH grant to uncover viral cause of MS

A team of investigators from the University of Utah has received a two-year, $275,000 grant from the National Institutes of Health (NIH) to fund novel research that may help to uncover a viral cause for the most acute and severe form of multiple sclerosis.

13 Oct 2011

Peanut allergy could be switched off

Now researchers may have discovered how to switch off food allergies. Researchers from Northwestern University found a way to tweak the immune system so that it doesn’t react when foods like peanuts and eggs are encountered – in mice.

12 Oct 2011

AAN Foundation launches new PSA on finding cure for brain disease

With one in six people in the United States now affected by brain disease such as dementia, multiple sclerosis and epilepsy, the American Academy of Neurology Foundation is marking its 20th anniversary with the launch of a new public service announcement (PSA) to raise awareness about the need for more research to cure brain disease.

12 Oct 2011

COPAXONE reduces loss of brain volume in patients with RRMS

Results from a five-year study of treatment-naïve patients with relapsing-remitting multiple sclerosis (RRMS) demonstrated that patients treated with COPAXONE (glatiramer acetate injection) showed significant reduced loss of brain volume compared to patients treated with other disease modifying therapies.

12 Oct 2011

PROLOR receives U.S. patent allowance for CTP-modified interferons

PROLOR Biotech, Inc. today announced that it received a notice of allowance from the U.S. Patent and Trademark Office (PTO) for a patent application covering PROLOR's CTP-modified interferons.

12 Oct 2011

Researchers identify cellular pathway to potentially block disease-inducing inflammation

Researchers have discovered a cellular pathway that promotes inflammation in diseases like asthma, rheumatoid arthritis, psoriasis, inflammatory bowel disease, and multiple sclerosis. Understanding the details of this pathway may provide opportunities for tailored treatments of inflammatory and autoimmune diseases.

10 Oct 2011

Teriflunomide drug reduces relapse rate of people with MS

A new oral drug has been shown in a large international clinical trial to significantly reduce the relapse rate of people with multiple sclerosis and to slow the progression of the disease.

7 Oct 2011

New review finds inconsistency in studies that examine link between CCSVI and MS

Studies that examined the possible link between vein blockages and multiple sclerosis are so inconsistent that it's impossible to reach a firm conclusion about the controversial theory, a new review has found.

4 Oct 2011

Roundup: Blue Shield of Calif. drops coverage of controversial drug in breast cancer treatment; Perry presses stem cell therapy

Blue Shield of California will no longer pay for the use of the drug Avastin to treat breast cancer, a sign that support for the widely debated and expensive treatment may be eroding among health plans.

4 Oct 2011

La Jolla Institute scientist identifies previously unknown T cell interaction

Most of the time, the immune system is the body's protector, warding off invading viruses and bacteria before they can lead to infection and disease. But in autoimmune diseases, the immune system does an about face, turning on the body and attacking normal cells.

3 Oct 2011

Planned clinical trial of Adeona's zinc-based therapy for ALS patients to be featured at ALS Summit

Adeona Pharmaceuticals, Inc., a developer of innovative medicines for serious central nervous system diseases, announced today that its planned clinical trial of the Company's proprietary zinc-based therapy for patients suffering from amyotrophic lateral sclerosis, also known as Lou Gehrig's Disease, will be featured during the Hot Topics session at the 2011 California ALS Research Summit on Saturday, October 1, 2011.

1 Oct 2011

Express Scripts launches suite of services through HealthBridge Pharma & Biotech

Express Scripts has launched a suite of services for pharmaceutical and biotech companies through HealthBridge Pharma & Biotech, providing a single-solution approach to patient care.

1 Oct 2011

CoreValve prosthesis shows promise against severe aortic stenosis

Among individuals 65 years and older, as many as 30 percent have aortic valve sclerosis or stenosis and as a result of their deteriorating health, cannot enjoy a normal lifestyle. "The aortic valve is a gatekeeper," says Marco Costa, MD, of University Hospitals (UH) Case Medical in Cleveland.

From Medtronic 1 Oct 2011